10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 2,500,000 | $117,600,000 | +297% | 4.38% |
| 2. | Vestal Point Capital Ryan Wilder | 2,350,000 | $110,544,000 | +57% | 6.55% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,196,721 | $103,333,756 | -7% | 0.57% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,153,313 | $101,291,843 | +15% | 0.12% |
| 5. | OrbiMed Advisors Samuel Isaly | 1,584,005 | $74,511,595 | +107% | 1.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | Director | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | Large Shareholder | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | Large Shareholder | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | Large Shareholder | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | Large Shareholder | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.43 | 450 | Director | 14,658 | 2025-04-03 | Filing | |
| $40.75 | 15,000 | Officer, Director | 427,629 | 2025-03-31 | Filing | |
| $43.58 | 2,000 | Officer | 140,455 | 2025-03-18 | Filing | |
| $44.38 | 2,775 | Officer | 34,888 | 2025-03-17 | Filing | |
| $44.38 | 4,389 | Officer | 101,005 | 2025-03-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 202,000 | $231,189 | 0.03% | |
| 2. | 68,000 | $77,826 | 0% | |
| 3. | 192 | $7,716 | 0% | |
| 4. | 0 | $0 | 0% |
News See All
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Cytokinetics' Fourth Quarter 2024 Conference Call. At this time, I would like to inform you that this call is being recorded.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
12 Best Healthcare Stocks to Buy According to Analysts
McKinsey reported that, since 2019, the US healthcare industry witnessed significant financial pressure.
10 Stocks That Analysts Are Talking About
Like any other informed investor, we are always on the hunt for stocks that analysts are talking about.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Call Transcript November 6, 2024Cytokinetics, Incorporated misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
Billionaire Hedge Funds
